All Roll Calls
Yes: 127 • No: 1
UtahS.B. 2222026 General SessionSenate
Right to Try Amendments
Sponsored By: Chris H. Wilson (Republican)
Signed by Governor
Health and Human ServicesHealth Care
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
More patients can seek experimental treatments
Beginning May 6, 2026, Utah expands which patients can seek experimental drugs or devices through its right-to-try law. A doctor licensed under Utah’s medical or osteopathic practice laws must diagnose a terminal or eligible illness. An eligible illness must pose a substantial risk that is severely disabling or life-threatening. Conventional treatments must have been explored, with no satisfactory option or option comparable to the experimental treatment. Terminal illness includes a condition that inevitably leads to death and poses greater risk than the experimental treatment. It also includes cancer as determined by a board-certified cancer doctor. Terminal patients must have exhausted conventional treatments and have no satisfactory or comparable option. Covered dosage forms include tablets, capsules, concentrated oils, liquid formulations, skin preparations, and preparations taken under the tongue. Liquid formulations replace the narrower reference to liquid suspensions. Eligibility does not guarantee that a manufacturer provides treatment.
Tighter rules for experimental treatment access
Beginning May 6, 2026, qualifying experimental drugs and devices must meet federal definitions and have completed FDA Phase 1 testing. Drugs must meet Part 312 rules, and devices must meet Part 812 rules. For an eligible illness, devices must remain under investigation, and drugs must remain in a Part 312 clinical investigation. Manufacturers providing these products to Utah patients must report to the Health and Human Services Interim Committee before the following November 1. Reports must list the number of patients treated for eligible illnesses, each illness treated, and adverse outcomes likely caused by treatment. Manufacturers also include any other information they consider relevant. Reporting is not required when the patient participated in an FDA-regulated investigation under Part 312 or Part 812.
Sponsors & Cosponsors
Sponsor
Chris H. Wilson
Republican • Senate
Cosponsors
Clancy, Tyler
Affiliation unavailable
Roll Call Votes
House vote • 3/5/2026
House/ passed 3rd reading
Yes: 67 • No: 0
House vote • 2/27/2026
House Comm - Favorable Recommendation
Yes: 10 • No: 0
Senate vote • 2/23/2026
Senate/ passed 3rd reading
Yes: 24 • No: 0
Senate vote • 2/23/2026
Senate/ uncircled
Yes: 0 • No: 0
Senate vote • 2/23/2026
Senate/ circled
Yes: 0 • No: 0
Senate vote • 2/23/2026
Senate/ substituted
Yes: 0 • No: 0
Senate vote • 2/20/2026
Senate/ substituted
Yes: 0 • No: 0
Senate vote • 2/20/2026
Senate/ passed 2nd reading
Yes: 23 • No: 0
Senate vote • 2/3/2026
Senate Comm - Favorable Recommendation
Yes: 3 • No: 1
Actions Timeline
Governor Signed
3/18/2026Senate/ to Governor
3/13/2026SenateSenate/ received enrolled bill from Printing
3/13/2026SenateSenate/ enrolled bill to Printing
3/11/2026SenateEnrolled Bill Returned to House or Senate
3/11/2026Draft of Enrolled Bill Prepared
3/6/2026Bill Received from Senate for Enrolling
3/6/2026Senate/ signed by President/ sent for enrolling
3/6/2026SenateSenate/ received from House
3/6/2026SenateHouse/ to Senate
3/5/2026HouseHouse/ signed by Speaker/ returned to Senate
3/5/2026HouseHouse/ passed 3rd reading
3/5/2026HouseHouse/ 3rd reading
3/5/2026HouseHouse/ 2nd reading
3/2/2026HouseHouse/ committee report favorable
3/2/2026HouseHouse Comm - Favorable Recommendation
2/27/2026House/ to standing committee
2/25/2026HouseHouse/ 1st reading (Introduced)
2/24/2026HouseHouse/ received from Senate
2/23/2026HouseSenate/ to House
2/23/2026SenateSenate/ passed 3rd reading
2/23/2026SenateSenate/ uncircled
2/23/2026SenateSenate/ circled
2/23/2026SenateSenate/ substituted
2/23/2026SenateSenate/ 3rd reading
2/23/2026Senate
Bill Text
Enrolled
3/11/2026
Substitute #2
2/23/2026
Substitute #1
2/17/2026
Introduced
1/29/2026